Psychedelic medicines are drawing renewed attention in neuroscience and mental health research because of their potential to help shift deeply ingrained emotional and behavioral patterns. Psychedelic medicines such as psilocybin, LSD, DMT, MDMA, and ketamine are generating great interest in mental health and neuroscience because in many people, they appear to shift long-standing emotional and […]
Understanding anxiety disorders Anxiety disorders are among the most common mental health challenges, affecting more than 40 million U.S. adults each year. Conditions such as generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder can severely impact daily functioning, relationships, and overall quality of life. Anxiety causes the most emergency room visits and mood […]
Ketamine in Clinical Practice Ketamine was originally developed in the 1960s as an anesthetic and has been used in medicine for many years. It is also being studied for certain mental health conditions and chronic pain. The strongest evidence is for depression, while research for anxiety, PTSD, OCD, substance use, and chronic pain is still […]
This Phase III, randomised, quadruple-masked, placebo-controlled crossover trial (n=20 completers) will evaluate whether adding low-dose ketamine to subcutaneous morphine improves analgesia in hospitalised adults aged 18–70 years with neuropathic cancer pain that remains inadequately controlled despite continuous morphine infusion. Participants will receive ketamine 1 mg/kg per 24 hours or sodium chloride 0.9% as a separate […]
This Phase II, multicentre, open-label randomised controlled trial (n=230) will evaluate the long-term efficacy and safety of intravenous ketamine maintenance treatment in adults with treatment-resistant depression (TRD) and a current moderate or severe depressive episode. The primary outcomes are time to relapse after the induction phase and after the final ketamine infusion, assessed using clinician-rated […]
This therapeutic exploratory trial (n=30, withdrawn), sponsored by MAPS Europe B.V., Netherlands, aimed to assess the long-term safety and persistence of effectiveness of manualized MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD).Detailed Description Long-term follow-up study of participants previously enrolled in MAPS Europe MDMA-assisted therapy trials for PTSD to assess persistence of treatment […]
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!